DR SANKET ISHWARBHAI SHAH (Orcid ID : 0000-0003-3224-1151)

DR SAIBAL DAS (Orcid ID : 0000-0002-3153-4166)

DR AVINASH JAIN (Orcid ID : 0000-0003-3207-4509)

DR DURGA PRASANNA MISRA (Orcid ID : 0000-0002-5035-7396)

DR V S NEGI (Orcid ID : 0000-0003-1518-6031)

Article type   : Original Article

A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19)

Sanket Shah,[1] Saibal Das,[2] Avinash Jain,[3] Durga Prasanna Misra,[4] Vir Singh Negi[1]*

[1]Department of Clinical Immunology, JIPMER, Puducherry, India

[2]Department of Clinical Pharmacology, JIPMER, Puducherry, India

[3]Department of Clinical Immunology and Rheumatology, MGMC&H, Jaipur, India

[4]Department of Clinical Immunology and Rheumatology, SGPGIMS, Lucknow, India

Running title

CQ and HCQ as prophylaxis in COVID-19

*Corresponding author

Name: Dr. Vir Singh Negi

Address: Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry: 605 006, India

Email ID: vsnegi22@yahoo.co.in

Tel No.: +919443433974

Author contributions

SS and VSN have conceptualized the review; SS, SD, and AJ were involved in literature search and study selection; SS and DPM were involved in disagreement resolution and finalization of the included studies; SS, SD, and AJ have extracted data from the studies for qualitative synthesis of evidence; DPM, and VSN have interpreted the analyses; SS, SD, and AJ have drafted the review; DPM and VSN have provided expert inputs and updated the final review.

Abstract

Objective: The pandemic Coronavirus Disease-19 (COVID-19) has pushed the global healthcare system to a crisis and amounted to a huge economic burden. Different drugs for prophylaxis against COVID-19 including chloroquine (CQ) or hydroxychloroquine (HCQ) have been tried. This study was performed to systematically review the role of CQ and HCQ in preventing the spread of COVID-19.

Methods: PubMed, EMBASE, ClinicalTrials.gov, ICTRP, and Cochrane Library databases were searched for studies that evaluated the prophylactic role of CQ or HCQ on SARS-CoV-2 (pre-clinical studies) or COVID-19 (clinical studies) until 30 March 2020. The available literature was critically appraised.

Results: A total of 45 articles were screened and five (three *in vitro* pre-clinical studies and two clinical opinions) were included. The pre-clinical studies showed the prophylactic effects of CQ and HCQ against SARS-CoV-2. On the other hand, the clinical opinions advocated the prophylactic use of CQ and HCQ against COVID-19. However, no original clinical studies on the prophylactic role of CQ or HCQ on COVID-19 were available.

Conclusion: Although pre-clinical results are promising, till date, there is dearth of evidence to support the efficacy of CQ or HCQ in preventing COVID-19. Considering potential safety issues and the likelihood of imparting a false sense of security, prophylaxis with CQ or HCQ against COVID-19 needs to be thoroughly evaluated in observational studies or high quality randomized controlled studies.

Keywords: Prevention, high-risk, chloroquine, hydroxychloroquine, SARS-CoV-2, COVID-19.

Introduction

The present world is experiencing a pandemic (Coronavirus Disease-19 or COVID-19) caused by a novel strain of coronavirus, called SARS-CoV2, previously called 2019-CoV. At the time of writing this article, 3,72,757 cases spanning over 195 countries and territories and one international conveyance have been reported [1]. This could be an underestimate due to the lower number of diagnostic tests and case identification partly due to poor health services in most countries. The mortality rate stands at 0.5–4.4% [2], however, this could be an overestimate as the exact denominator of actual number of cases are underreported. Diversion of all health care facilities towards COVID-19 pandemic is likely to increase the morbidity and mortality due to other health problems. In such a scenario, understanding the impact on economy is beyond the confines of a medical expert.

Another conundrum faced is a high secondary infection rate amongst the high-risk health care workers annexing the already burdened healthcare system [3]. This would not only compound the impending shortage of health care facilities but would also mean more pervasive spread. Prevention is thus the best strategy to not only prevent more spread and deaths but also to offload the health care system. However, there are challenges involved. Although methods like mitigation, quarantine, isolation, social distancing, etc. are being employed, these are not infallible. Contact tracing for the spread of infection from asymptomatic or mild undiagnosed cases, transition to community spread, and factors, such as uncertainty regarding the survival of virus in air or fomites are cumulatively adding to the mammoth task [4]. Hence, the focus has now been shifted towards evaluating and implementing other strategies like chemoprophylaxis and vaccination besides the continued use of the barrier system. Vaccine development will take time between 12–18 months as human trials are under way. There is a lot of speculation on chemoprophylaxis stemming from the available data on the use of some antimalarial drugs, such as chloroquine (CQ) and hydroxychloroquine (HCQ), which have been tried for the treatment of this disease [5].

The potential drug targets depend on the natural cycle of this virus. The virus depends on pH-dependent internalization and fusion with lysosomes. HCQ and CQ target this pathway by increasing the pH as they get concentrated into the lysosome and endosomes. This, in turn, affects viral replication and also helps in immune regulation and prevention of cytokine storm as the antigen presentation is affected. But the challenge is the translational impact of *in vitro* models to *in vivo*

ones. There are studies from China and other countries highlighting the use of anti-malarial anthraquinones including mention of the same in latest guidelines [6,7]. A recent advisory issued by a national body from a South-Asian country suggested the use of prophylactic hydroxychloroquine at a dose of 400 mg twice daily, followed by once weekly, for healthcare workers managing patients with COVID-19 and close contacts of proven COVID-19 cases [8]. However, these studies and guidelines differ on the prophylactic use of these drugs causing further dilemma amongst the health care professionals. Hence, we aimed to systematically review the literature on the role of CQ or HCQ in preventing the spread of COVID-19.

Methods

Study design

We aimed to include all completed and published pre-clinical as well as clinical studies, without limitations, which evaluated the prophylactic role of CQ or HCQ on SARS-CoV-2 (pre-clinical studies) or COVID-19 (clinical studies). We also looked for commentaries, reviews, viewpoints, or opinions if original clinical studies were not available. Studies which evaluated the therapeutic effects of CQ or HCQ were excluded.

Search strategy

PubMed, EMBASE, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, and Cochrane Library [Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials (CENTRAL), and Cochrane Methodology Register] were searched from inception until 30 March 2020. The search terms used in various combinations were: "chloroquine", "hydroxychloroquine", "anthraquinone", "CQ", "HCQ", "coronavirus", "coronavirus disease", "Coronavirus Disease-19", "COVID-19", "severe acute respiratory syndrome", "SARS-CoV-2", "prophylaxis", and "preventive". These search terms were adapted for use with different bibliographic databases in combination with database-specific filters for studies, if available. The search strategy was used to obtain the titles and the abstracts of the relevant studies in English, and they were independently screened by two authors, who subsequently retrieved abstracts, and if necessary, the full text of articles to determine the suitability. Disagreement resolution was done with a third author.

The systematic review protocol could not be pre-registered as the current pandemic is an ongoing public health emergency, thereby resulting in a paucity of time to permit pre-registration.

Appraisal of the selected articles

The clinical opinions were critically appraised following the checklist of McArthur, et al., 2015 [9]. The characteristics of the pre-clinical studies were also critically appraised. This was performed independently by two authors, and disagreement resolution was done with a third author. No assumptions or simplifications were made during the process.

Results

At total of 45 articles were screened and three *in vitro* pre-clinical studies [10–12] and two clinical opinions [13,14] were included in the analysis. No original clinical studies on the prophylactic role of CQ or HCQ on COVID-19 were available (Figure 1). Table 1 enumerates the findings of the in vitro pre-clinical studies and Table 2 denotes the critical appraisal of the clinical opinions. The pre-clinical studies showed the prophylactic effects of CQ and HCQ against SARS-CoV-2. While Yao et al. showed that HCQ exhibited a better in vitro anti-SARS-CoV-2 activity than CQ in Vero cells derived from the African green monkey kidney, Liu et al. exhibited a higher potency of CQ over HCQ in the same cell line. Xiao et al. enumerated that CQ and remdesvir (which inhibits RNA polymerase), as compared to five other drugs, had a better *in vitro* potency in inhibiting SARS-CoV-2 in Vero cell line. On the other hand, both Zhou et al. and Colson et al. provided their clinical opinions advocating the possible prophylactic use of CQ and HCQ against COVID-19. On appraisal, both the articles were found to be of reasonable quality.

Discussion

The first *in vitro* study pointing towards the role of CQ and HCQ as pre-exposure prophylaxis against COVID-19 was published as a research letter by Yao et al [10]. Vero cell line derived from African green monkey kidney were treated with CQ or HCQ before exposing to clinically isolated novel coronavirus strain (C-Tan-nCoV Wuhan strain 01) at a multiplicity of infection (MOI) of 0.05. HCQ was more potent than CQ in achieving the 50% maximal effective concentration (EC_{50}) (6.25 and 5.85 μM at 24 and 48 h, respectively). The concentration to achieve EC_{50} was >100 and 18.01 μM for

CQ, suggesting a higher loading dose. This study led to the enthusiasm of registration of clinical trials on the prophylactic role CQ and HCQ (Table 3). The study also highlighted the use of a high loading dose of CQ followed by a low maintenance dose to support its pharmacokinetic property of higher cellular accumulation and prolonged elimination half-life. Another *in vitro* study by a different group of researchers from China compared HCQ to CQ at four different MOI [11]. The results were contradictory to that of the previous study showing a lower EC_{50} of CQ than that of HCQ. Importantly the difference was even more striking at higher MOI, suggesting that in the presence of faster multiplication of the virus, CQ may perform better than HCQ. The possible reasons for the conflicting results are challenging to explain, however, it cautiously points towards extrapolation of *in vitro* evidence to clinical practice without robust clinical data. This also puts a question mark on the preventive role where the therapeutic effect of CQ might not be adequate. In another published study, Xiao et al. assessed the role of multiple US Food and Drug Administration-approved anti-viral drugs, including CQ (Table 2) [12]. Their time-of-addition assay demonstrated that CQ functioned at both entry and post-entry stages of the SARS-CoV-2 infection in Vero E6 cells. The concentration to achieve EC_{50} and EC_{90} were 1.13 μM and 6.90 μM, respectively.

Based on these *in vitro* results, some authors have adjudicated the prophylactic use of CQ and HCQ against COVID-19. Following the concept of drug repositioning, CQ and HCQ were proposed to be used against SARS-CoV-2 in an editorial published by a French group in February 2020 [14]. It was also supported with the already established *in vitro* antiviral efficacy of CQ in other viruses, as well as against SARS-CoV-2. They emphasized the potential cost-benefit ratio of this prophylactic approach as a hope for the overburdened health care system during this pandemic. On 20 March 2020, researchers from China published a concise report emphasizing the role of HCQ over CQ as a prophylactic drug [13]. The report highlighted the *in vitro* prophylactic effects of HCQ and elaborated the molecular mechanisms of its antiviral activity. The maximum daily dose of CQ is 500 mg, while HCQ can be given at a higher daily dose of 1200 mg, which is equivalent to 750 mg of CQ. HCQ, at a higher dose, may have a more potent antiviral activity as compared to that of CQ. Furthermore, HCQ has a better safety profile due to a lesser tissue accumulation as compared to CQ. An additional advantage of HCQ is its safety in pregnancy unlike CQ [15]. Thus, if proven beneficial, HCQ may be a prophylactic drug against COVID-19.

Clinical trials are underway to assess the translational impact of the *in vitro* prophylactic benefits of CQ and HCQ against COVID-19. Five ongoing clinical trials are aiming to assess the prophylactic efficacy of CQ and HCQ, although there is no mention of any planned interim analysis. With the paucity of evidence on the prophylactic use of these drugs, there are additional essential concerns to address. Despite the *in vitro* antiviral efficacy, CQ has failed to show efficacy in *in vivo* guinea pig model of Ebola [16], and ferret model of Nipah virus [17] and influenza virus [18]. Clinical trials of CQ as prophylaxis failed in influenza [19] despite strong *in vitro* efficacy [18]. Even in chikungunya, the viral replication paradoxically enhanced in animal models after CQ administration [20]. In a clinical trial, long term musculoskeletal symptoms were more in patients treated with CQ as compared to placebo [20]. Another critical concern is the toxicity of these drugs. CQ has a narrow safety margin and may cause several cardiovascular adverse effects, including QT prolongation, as well other unforeseen adverse reactions [21]. HCQ is relatively safer. However, unrestricted acute overdosing of these drugs can lead to serious toxicities. Moreover, these adverse events may get augmented due to potential drug inhibitors like CYP inhibitors, as well as with other drugs being advocated or evaluated in COVID-19 such as azithromycin [22] and protease inhibitors [23,24].

In the absence of robust *in vivo* and clinical evidence, it seems premature to recommend CQ and HCQ as a panacea for prophylaxis of COVID-19. In the current COVID-19 pandemic, quarantine, social distancing, and personal hygiene seem the only proven preventative measures [25]. It is pertinent to mention here that from the regulatory point of view, there is a mixed opinion on the prophylactic use of CQ or HCQ in different countries. Injudicious use of CQ and HCQ in the light of scarcity of evidence may indulge a false sense of protection hampering the essential precautionary measures by the common mass. Furthermore, the pandemic hysteria leading to unrestricted off-label use of these drugs by the common mass without adhering to the guidelines may lead to deprivation of these essential drugs to other legitimate patients of lupus and rheumatoid arthritis or malaria if production does not match the demand. There are already reports of adverse effects published in newspaper including death and hospitalization [26]. Thus, further prudency is warranted in this regard.

Re-emphasizing the fact that chemoprophylaxis against COVID-19 is the need of the hour, the related socioeconomic issues need to be addressed. There are reports of the ostracization of healthcare workers and other individuals from the affected places [27,28]. Hence, targeted prophylaxis of high-risk

individuals can serve the purpose of social security apart from health benefits. However, the primary objective of prophylaxis is defied if a drug use, without concrete scientific evidence, leads to mass hysteria and depriving the legitimate population, such as patients with lupus and rheumatoid arthritis, for the use of these drugs [29]. If CQ and HCQ show prophylactic efficacy in the ongoing clinical trials, targeted prophylaxis may be recommended over mass prophylaxis in the future.

There are limitations to our study. As of date, there is a dearth of adequate data on this topic of interest. Pre-clinical and clinical studies are ongoing, and most likely new information will be added to the existing literature in the near future necessitating updating this review. Notwithstanding these limitations, we have shown that there is absence of a clear evidence to support the efficacy of CQ or HCQ in preventing COVID-19.

Conclusion

The pandemic Coronavirus Disease-19 (COVID-19) has pushed the global healthcare system to a crisis and amounted to a huge economic and societal burden. Prevention of transmission of the disease in the population, particularly among high-risk individuals, is the urgent need of the hour. Different drugs for prophylaxis against COVID-19 including CQ or HCQ have been tried. Although pre-clinical results are promising, till date, there is dearth of good quality evidence to support the clinical efficacy of CQ or HCQ in preventing COVID-19. Because of the lack of robust clinical evidence till date and duly considering the questionable efficacy, safety concerns, danger of deprivation of these essential drugs to legitimate patients due to panic stocking and instilling a false sense of protection among the common mass, the prophylactic use of CQ or HCQ against COVID-19 needs to be further reviewed as more data pour in.

Conflict of interest

The authors declare that there is no conflict of interest associated with this manuscript.

Funding

No funding or support was received for the work.

References

1. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 64 [Internet]. 2020 [cited 2020 Mar 25]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200324-sitrep-64-covid-19.pdf?sfvrsn=703b2c40_2

2. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020;

3. The Lancet null. COVID-19: protecting health-care workers. Lancet Lond Engl. 2020;395:922.

4. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020;

5. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;advpub.

6. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949.

7. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition) [Internet]. China National Health Commision; 2020. Available from: http://kjfy.meetingchina.org/msite/news/show/cn/3337.html#

8. Indian Council of Medical Research. Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection [Internet]. 2020 [cited 2020 Mar 24]. Available from: https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf

9. McArthur A, Klugárová J, Yan H, Florescu S. Innovations in the systematic review of text and opinion. Int J Evid Based Healthc. 2015;13:188–95.

10. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis Off Publ Infect Dis Soc Am. 2020;

11. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:1–4.

12. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–71.

13. Zhou D, Dai S-M, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother [Internet]. [cited 2020 Mar 24]; Available from: https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa114/5810487

14. Colson P, Rolain J-M, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020;55:105923.

15. Sperber K, Hom C, Chao CP, Shapiro D, Ash J. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol. 2009;7:9.

16. Dowall SD, Bosworth A, Watson R, Bewley K, Taylor I, Rayner E, et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol. 2015;96:3484–92.

17. Pallister J, Middleton D, Crameri G, Yamada M, Klein R, Hancock TJ, et al. Chloroquine Administration Does Not Prevent Nipah Virus Infection and Disease in Ferrets. J Virol. 2009;83:11979–82.

18. Vigerust DJ, McCullers JA. Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respir Viruses. 2007;1:189–92.

19. Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis. 2011;11:677–83.

20. Roques P, Thiberville S-D, Dupuis-Maguiraga L, Lum F-M, Labadie K, Martinon F, et al. Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection. Viruses. 2018;10:268.

21. Vinetz J. Chemotherapy of Malaria. In: Brunton L, Hilal-Dandan R, Knollmann B, editors. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. New York, NY: McGraw-Hill Education; 2018. p. 969–86.

22. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949.

23. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;0:null.

24. Mason JW. Antimicrobials and QT prolongation. J Antimicrob Chemother. 2017;72:1272–4.

25. Wilder-Smith A, Freedman DO. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. J Travel Med. 2020;27.

26. Coronavirus: We are now receiving patients suffering from chloroquine poisoning, says Lagos govt, NCDC cautions Nigerians [Internet]. Tribune Online. 2020 [cited 2020 Mar 24]. Available from: https://tribuneonlineng.com/coronavirus-we-are-now-receiving-patients-suffering-from-chloroquine-poisoning-says-lagos-govt-ncdc-cautions-nigerians/

27. CNN HY Natasha Chen and Dushyant Naresh. What's spreading faster than coronavirus in the US? Racist assaults and ignorant attacks against Asians [Internet]. CNN. [cited 2020 Mar 24]. Available from: https://www.cnn.com/2020/02/20/us/coronavirus-racist-attacks-against-asian-americans/index.html

28. While people clapped for those in front line fighting virus, Telangana landlords leave doctors homeless [Internet]. The New Indian Express. [cited 2020 Mar 24]. Available from: https://www.newindianexpress.com/states/telangana/2020/mar/24/while-people-clapped-for-those-in-front-line-fighting-virus-telangana-landlords-leave-doctors-homele-2120839.html

29. American College of Rheumatology. Hydroxychloroquine and COVID-19 [Internet]. [cited 2020 Mar 25]. Available from: https://www.rheumatology.org/announcements

Figure legend

Figure 1. Flowchart depicting the steps of qualitative synthesis of evidence from the literature.

Table 1. Characteristics of the *in vitro* pre-clinical studies.

Characteristics	Studies		
	Yao et al., 2020	**Liu et al., 2020**	**Xiao et al., 2020**
Cell lines used	Vero cells derived from the African green monkey kidney	Vero cells derived from the African green monkey kidney	Vero E6 cells from the African green monkey kidney and Huh7 Human liver cancer cells[†]
Study drugs	CQ and HCQ	CQ and HCQ	CQ and others[‡]
Drug concentrations and duration	0.032, 0.16, 0.80, 4, 20, and 100 µM for 2 h	0.068, 0.21, 0.62, 1.85, 5.56, 16.67, and 50 µM for 1 h	1.11, 3.33, and 10 µM for 1h
Comparator	None	Phosphate-buffered saline (control)	DMSO
50% maximal effective concentration (EC_{50})	Higher for CQ than that of HCQ	Lower for CQ than that of HCQ	Lower for CQ and remdesvir than others[‡]
Key findings	• HCQ exhibited a better in vitro anti-SARS-CoV-2 activity than CQ • Longer incubation time may provide a better antiviral effect	• The anti-viral effects of HCQ seemed to be less potent than that of CQ, especially at a higher viral replication rate • The entry step as well as the post entry steps of virus infection were inhibited by HCQ	• CQ and remdesvir blocked virus infection at a low-micromolar concentration • Full-time, entry, as well as post entry steps were inhibited by CQ and remdesvir

†Remdesvir

‡Other drugs included ribavirin, penciclovir, nitazoxanide, nafamostat, remdesivir (GS- 5734), and favipiravir (T-705)

(CQ, chloroquine; DMSO, dimethyl sulfoxide; h, hour; HCQ, hydroxychloroquine)

**Table 2.** Critical appraisal of the clinical opinions.[9]

Checklist	Studies	
	Zhou et al., 2020	Colson et al., 2020
Is the source of the opinion clearly identified?	Yes	Yes
Does the source of opinion have standing in the field of expertise?	Yes	Yes
Are the interests of the relevant population the central focus of the opinion?	Yes	Yes
Is the stated position the result of an analytical process, and is there logic in the opinion expressed?	Yes	Yes
Is there reference to the extant literature?	Unclear	Unclear
Is any incongruence with the literature/sources logically defended?	Yes	No
Is the opinion supported by peers?	Unclear	Unclear

Table 3. Ongoing clinical studies evaluating the prophylactic role of CQ and HCQ against COVID-19 (search conducted on clinicaltrials.gov on 30 March 2020)

Study registration no. (country)	Recruitment status	No. of Centers and study design	Population (volunteers)	Interventional group(s)	Comparison Group(s)	Primary Outcomes
NCT04308668 (USA)	Recruiting	Multi-center randomized parallel group trial	1500 participants (contact or healthcare worker exposed to a patient with COVID-19)	HCQ	Placebo	Incidence and severity of COVID-19
NCT04304053 (Spain)	Recruiting	Multi-center cluster randomized trial	3040 participants (Contacts of patients with COVID-19)	Antiviral treatment and prophylaxis with HCQ	Standard public health measures	Incidence of secondary COVID-19 cases
NCT04303507 (Europe & Asia)	Not yet recruiting	Multi-center randomized parallel group trial	40000 participants (contact or healthcare	CQ or HCQ	Placebo	Number of symptomatic COVID-19 infections

			worker exposed to a patient with COVID-19)			
NCT0431 8444 (USA)	Not yet recruiting	Community-Based Randomized Clinical Trial	1600 participants (adult household contacts of COVID-19 patients	HCQ	Placebo	Number of participants with symptomatic, lab-confirmed COVID-19
NCT04318 015 (Mexico)	Not yet recruiting	Parallel group RCT	400 participants (healthcare workers attending to COVID-19 patients)	HCQ	Placebo	Symptomatic COVID-19

(CQ, chloroquine; HCQ, hydroxychloroquine)

Records identified through PubMed, EMBASE, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, and Cochrane Library until 30 March 2020 (n = 45)

Studies excluded (n = 31) (Inappropriate disease, inappropriate population, inappropriate intervention)

Potential studies identified after screening (n = 14)

Articles related to the therapeutic use of the study drugs (n = 4), other review articles/commentaries (n = 5)

Studies included in qualitative synthesis (n = 5)

Pre-clinical *in vitro* studies (n = 3)

Clinical opinions (n = 2)

apl_13842_f1.tiff